Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

Bright Minds Biosciences (NASDAQ: DRUG) will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 4:20 PM EDT, with a live and archived webcast available on its investor website for 30 days.

Rhea-AI Summary

Bright Minds Biosciences (NASDAQ: DRUG) will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 4:20 PM EDT, with a live and archived webcast available on its investor website for 30 days.

The company also granted 109,000 stock options to directors, officers and consultants, exercisable at US$83.40 per share for five years, vesting in four equal annual 25% installments starting one year from grant.

Argus May 27 session

+0.88% close to close 1.1x rel. volume Open Argus

Details

News Market Reaction – DRUG

On May 27, the first trading day after this news, DRUG closed 0.88% above the previous close.

Data tracked by StockTitan Argus for the May 27 session.

Key Figures

Options granted: 109,000 shares Option exercise price: US$83.40 per share Option term: 5 years +5 more

Options granted

109,000 shares

New stock options to directors, officers and consultants

Option exercise price

US$83.40 per share

Exercise price for newly granted options

Option term

5 years

Validity period from grant date

Vesting schedule

4 instalments of 25%

Annual vesting beginning on first anniversary

Conference date

June 3, 2026

Jefferies Global Healthcare Conference presentation

Conference time

4:20 PM EDT

Scheduled presentation time

Webcast replay

30 days

Duration replay remains accessible

Janus ownership

1,284,324 shares (13.1%)

Schedule 13G/A as of 03/31/2026

Historical Context

5 past events · Latest: Feb 25

5 events

1. Feb 25

   Investor conferences

   24h Move

   -5.0%

   Announced three investor conference presentations with webcast access details.

2. Jan 15

   Peer earnings date

   24h Move

   -2.1%

   Labcorp scheduled its Q4 2025 earnings release and conference call.

3. Jan 09

   Equity offering close

   24h Move

   -3.6%

   Closed US$175.05M public offering of 1,945,000 common shares at US$90.

4. Jan 07

   Equity offering pricing

   24h Move

   -6.2%

   Priced upsized US$175.05M public offering at US$90 per share.

5. Jan 06

   Equity offering launch

   24h Move

   +3.0%

   Launched US$100M public offering with 15% underwriter option.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

5-ht2 agonists, prader-willi syndrome, central nervous system (cns), stock options

4 terms

5-ht2 agonists medical

"focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy"

Drugs described as 5-HT2 agonists are medicines that act like a key fitting into a specific serotonin receptor (the 5-HT2 family) to switch that receptor on. Investors care because turning these receptors on can produce therapeutic effects (for conditions like mood, appetite or sleep) but also carries distinct safety and regulatory risks tied to which 5-HT2 subtype is affected, so trial results and approvals can strongly move a company’s value.

prader-willi syndrome medical

"for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other"

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

central nervous system (cns) medical

"depression, and other central nervous system (CNS) disorders, today announced that"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

stock options financial

"the Company has granted stock options (the “Options”) to certain directors, officers"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:

DATE:	Wednesday, June 3, 2026
TIME:	4:20PM EDT
WEBCAST:	Click Here

The live and archived webcast will be accessible from the Company’s website at https://investors.brightmindsbio.com/news-events/presentations under Events and Presentation. The replay of the webcast will be accessible for 30 days.

Bright Minds further releases that the Company has granted stock options (the “Options”) to certain directors, officers and consultants of the Company to purchase an aggregate of 109,000 common shares in the capital of the Company (the “Shares”) pursuant to the Company's share option plan. The Options are exercisable at a price of US$83.40 per Share for a period of five (5) years from the date of grant. The Options vest in four (4) equal annual instalments of 25% each, commencing on the first anniversary of the date of grant.

About Bright Minds Biosciences

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Bright Minds Biosciences (NASDAQ: DRUG) present at the Jefferies Global Healthcare Conference 2026?

Bright Minds Biosciences is scheduled to present on Wednesday, June 3, 2026, at 4:20 PM EDT. According to the company, investors can access a live and archived webcast of the presentation on its investor relations website under Events and Presentations.

How can investors access the Bright Minds Biosciences (DRUG) Jefferies Global Healthcare Conference webcast?

Investors can watch the Bright Minds presentation via a live webcast available on the company’s investor site. According to Bright Minds, an archived replay of the Jefferies Global Healthcare Conference webcast will remain accessible for 30 days under Events and Presentations.

What stock options did Bright Minds Biosciences (DRUG) grant on May 26, 2026?

Bright Minds granted options to purchase 109,000 common shares to certain directors, officers and consultants. According to the company, these options are exercisable at US$83.40 per share for five years, with vesting in four equal annual 25% installments beginning one year from the grant date.

What is the vesting schedule for the new Bright Minds Biosciences (DRUG) stock option grant?

The granted options vest in four equal annual installments of 25% each. According to Bright Minds, vesting starts on the first anniversary of the grant date and continues annually, fully vesting after four years if conditions are satisfied.

What is the exercise price and term of the new Bright Minds Biosciences (DRUG) options?

The newly granted stock options have an exercise price of US$83.40 per common share and a five-year term. According to Bright Minds, holders may exercise these options any time within that period, subject to the vesting schedule and applicable plan conditions.